Orforglipron is also generally easier and cheaper to manufacture than injectable GLP-1s, which could lower costs and improve availability. And early studies have suggested it may remain effective for longer before the body becomes less responsive to treatment.[1]
Here are the differences between Foundayo and other popular weight loss treatments:
Orforglipron vs. tirzepatide (Mounjaro)
Tirzepatide currently appears to produce greater overall weight loss in clinical trials.[2] However, Foundayo may be a more practical option for people who prefer pills over injections.
Orforglipron vs. semaglutide (Wegovy)
Studies suggest that orforglipron (Foundayo) may lead to greater weight loss than oral semaglutide (the active ingredient in the Wegovy pill)[3]:
Orforglipron: 9.2% at 36mg and 6.7% weight loss at 12mg
Oral semaglutide: 5.3% at 14mg and 3.7% weight loss at 7mg
Many people may also find it easier to take, as it doesn’t need to be taken on an empty stomach, like the Wegovy pill, and then wait for at least 30 minutes before eating or drinking.
Orforglipron vs. retatrutide
Retatrutide (also sometimes called Triple-G, because it targets three hormone receptors) is an injectable treatment that has shown promising weight loss results.[4] But it’s still being evaluated in clinical trials, and is not yet available on the market.

